Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy MRNA?
Source: Benzinga
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 51.380
Low
17.00
Averages
32.47
High
63.00
Current: 51.380
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Administration Considers Candidates for CDC Leadership
- Candidate List: The Trump administration is considering Joseph Marine, a cardiologist from Johns Hopkins, and Ernie Fletcher, a former governor of Kentucky, as potential candidates for the CDC director position, highlighting contrasting views on vaccination policies.
- Position Vacancy: The CDC director role has been vacant for the third time since President Trump took office, with former acting director Jim O'Neil leaving in February and NIH director Jay Bhattacharya stepping in, indicating instability in CDC leadership.
- Divergent Vaccine Views: Marine has expressed skepticism about the need for repeated COVID-19 vaccinations in his Substack newsletter, while Fletcher received a COVID-19 shot in 2021 alongside other former governors, showcasing differing stances on vaccination between the candidates.
- Impact on Vaccine Manufacturers: The selection of candidates may influence market strategies of major vaccine manufacturers like Pfizer, AstraZeneca, and Merck, particularly regarding potential shifts in vaccination policies and public trust in vaccines.
See More
ImmunityBio's Anktiva Gains New Approvals and Momentum
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
See More
Pfizer vs. Moderna: Vaccine Market Competition Analysis
- Market Position Comparison: Pfizer, with a market cap of $156 billion, dominates the pharmaceutical industry, generating over $60 billion in annual revenue despite a decline in COVID vaccine sales, showcasing its strong market foundation and product portfolio.
- R&D Pipeline Potential: While Pfizer faces patent expirations, its extensive R&D pipeline is expected to make significant progress in the coming year, potentially positively impacting its stock price, although with less volatility.
- Moderna's Growth Potential: With a market cap of about $22 billion, Moderna's stock has surged 69% this year, primarily driven by positive clinical data from its cancer vaccine mRNA-4157, indicating its potential in the innovative vaccine space, albeit with FDA approval risks.
- Risk and Reward Trade-off: Pfizer's financial flexibility and stable dividend yield (6.3%) make it a lower-risk investment choice, while investors seeking high-risk, high-reward opportunities may prefer Moderna, despite its greater downside risks.
See More
Investment Comparison: Pfizer vs. Moderna
- Market Performance Divergence: Pfizer, with a market cap of $156 billion, generates over $60 billion in annual revenue despite declining COVID vaccine sales, showcasing its robustness in the pharmaceutical sector; in contrast, Moderna's market cap is only $22 billion, and while its stock has surged 69% this year, it faces higher volatility risks.
- Pipeline Potential: Pfizer boasts a deep product pipeline, and despite challenges from patent expirations, its R&D capabilities allow it to maintain stability during clinical advancements; conversely, Moderna is developing multiple mRNA vaccines, including for flu and HIV, which could significantly enhance its market position if successful.
- Financial Flexibility: Pfizer's financial strength enables it to manage clinical or regulatory setbacks by increasing R&D investments or acquiring new companies, whereas Moderna lacks such flexibility, and a potential FDA rejection of its vaccine could lead to a steep drop in its stock price.
- Dividend Yield: Pfizer offers a dividend yield of 6.3%, significantly higher than the S&P 500's 1.2%, with a 51.3% increase in dividends over the past decade, attracting investors seeking stable income; in contrast, Moderna does not pay dividends, appealing to those with a higher risk appetite.
See More
mRNA Vaccine Stocks Rise as HHS Committee Revises Recommendations
- Recommendation Revision: The HHS vaccines advisory committee has decided to walk back its previous threat to stop recommending mRNA vaccines, leading to a rise in stock prices for companies like Moderna and BioNTech during Wednesday's trading, indicating a restoration of market confidence in these vaccines.
- Positive Market Reaction: With the committee's adjustment, mRNA vaccines, widely used during the pandemic, are back in focus for investors, enhancing expectations for future vaccine demand for companies like Moderna (MRNA) and BioNTech (BNTX).
- Safety Controversies: Despite the positive signals from the committee's decision, some ACIP members have raised concerns about the potential harm of DNA elements in the vaccines, which could affect public acceptance and potentially impact future sales for these companies.
- Financial Outlook: BioNTech has outlined a revenue target of €2 billion to €2.3 billion for 2026, and despite facing leadership transitions and competitive pressures, the company continues to advance its late-stage oncology pipeline, demonstrating confidence in future growth.
See More
BioNTech's Strategic Shift and Clinical Progress
- Executive Transition: Co-founders Ugur Sahin and Özlem Türeci plan to lead a new venture by the end of 2026, prompting BioNTech's Supervisory Board to initiate a search for successors, which may impact the company's strategic direction and market confidence.
- Clinical Trial Progress: BioNTech expects to have 15 ongoing Phase 3 clinical trials by the end of 2026, covering major cancer types, with the resulting data informing regulatory and launch plans, potentially enhancing the company's competitiveness in oncology.
- Stock Performance: BioNTech's shares have decreased by 3.03% over the past 12 months, currently trading at $87.60, which is 18% below its 100-day simple moving average, reflecting a bearish market sentiment that could affect investor confidence.
- Market Momentum Analysis: With a Benzinga Edge score of 19.82 indicating weak momentum, BioNTech's stock is underperforming the broader market, although the strategic pivot may present future growth opportunities, current market sentiment remains negative.
See More
Trump Administration Considers Candidates for CDC Leadership
- Candidate List: The Trump administration is considering Joseph Marine, a cardiologist from Johns Hopkins, and Ernie Fletcher, a former governor of Kentucky, as potential candidates for the CDC director position, highlighting contrasting views on vaccination policies.
- Position Vacancy: The CDC director role has been vacant for the third time since President Trump took office, with former acting director Jim O'Neil leaving in February and NIH director Jay Bhattacharya stepping in, indicating instability in CDC leadership.
- Divergent Vaccine Views: Marine has expressed skepticism about the need for repeated COVID-19 vaccinations in his Substack newsletter, while Fletcher received a COVID-19 shot in 2021 alongside other former governors, showcasing differing stances on vaccination between the candidates.
- Impact on Vaccine Manufacturers: The selection of candidates may influence market strategies of major vaccine manufacturers like Pfizer, AstraZeneca, and Merck, particularly regarding potential shifts in vaccination policies and public trust in vaccines.
See More
ImmunityBio's Anktiva Gains New Approvals and Momentum
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
See More
Pfizer vs. Moderna: Vaccine Market Competition Analysis
- Market Position Comparison: Pfizer, with a market cap of $156 billion, dominates the pharmaceutical industry, generating over $60 billion in annual revenue despite a decline in COVID vaccine sales, showcasing its strong market foundation and product portfolio.
- R&D Pipeline Potential: While Pfizer faces patent expirations, its extensive R&D pipeline is expected to make significant progress in the coming year, potentially positively impacting its stock price, although with less volatility.
- Moderna's Growth Potential: With a market cap of about $22 billion, Moderna's stock has surged 69% this year, primarily driven by positive clinical data from its cancer vaccine mRNA-4157, indicating its potential in the innovative vaccine space, albeit with FDA approval risks.
- Risk and Reward Trade-off: Pfizer's financial flexibility and stable dividend yield (6.3%) make it a lower-risk investment choice, while investors seeking high-risk, high-reward opportunities may prefer Moderna, despite its greater downside risks.
See More
Investment Comparison: Pfizer vs. Moderna
- Market Performance Divergence: Pfizer, with a market cap of $156 billion, generates over $60 billion in annual revenue despite declining COVID vaccine sales, showcasing its robustness in the pharmaceutical sector; in contrast, Moderna's market cap is only $22 billion, and while its stock has surged 69% this year, it faces higher volatility risks.
- Pipeline Potential: Pfizer boasts a deep product pipeline, and despite challenges from patent expirations, its R&D capabilities allow it to maintain stability during clinical advancements; conversely, Moderna is developing multiple mRNA vaccines, including for flu and HIV, which could significantly enhance its market position if successful.
- Financial Flexibility: Pfizer's financial strength enables it to manage clinical or regulatory setbacks by increasing R&D investments or acquiring new companies, whereas Moderna lacks such flexibility, and a potential FDA rejection of its vaccine could lead to a steep drop in its stock price.
- Dividend Yield: Pfizer offers a dividend yield of 6.3%, significantly higher than the S&P 500's 1.2%, with a 51.3% increase in dividends over the past decade, attracting investors seeking stable income; in contrast, Moderna does not pay dividends, appealing to those with a higher risk appetite.
See More
mRNA Vaccine Stocks Rise as HHS Committee Revises Recommendations
- Recommendation Revision: The HHS vaccines advisory committee has decided to walk back its previous threat to stop recommending mRNA vaccines, leading to a rise in stock prices for companies like Moderna and BioNTech during Wednesday's trading, indicating a restoration of market confidence in these vaccines.
- Positive Market Reaction: With the committee's adjustment, mRNA vaccines, widely used during the pandemic, are back in focus for investors, enhancing expectations for future vaccine demand for companies like Moderna (MRNA) and BioNTech (BNTX).
- Safety Controversies: Despite the positive signals from the committee's decision, some ACIP members have raised concerns about the potential harm of DNA elements in the vaccines, which could affect public acceptance and potentially impact future sales for these companies.
- Financial Outlook: BioNTech has outlined a revenue target of €2 billion to €2.3 billion for 2026, and despite facing leadership transitions and competitive pressures, the company continues to advance its late-stage oncology pipeline, demonstrating confidence in future growth.
See More
BioNTech's Strategic Shift and Clinical Progress
- Executive Transition: Co-founders Ugur Sahin and Özlem Türeci plan to lead a new venture by the end of 2026, prompting BioNTech's Supervisory Board to initiate a search for successors, which may impact the company's strategic direction and market confidence.
- Clinical Trial Progress: BioNTech expects to have 15 ongoing Phase 3 clinical trials by the end of 2026, covering major cancer types, with the resulting data informing regulatory and launch plans, potentially enhancing the company's competitiveness in oncology.
- Stock Performance: BioNTech's shares have decreased by 3.03% over the past 12 months, currently trading at $87.60, which is 18% below its 100-day simple moving average, reflecting a bearish market sentiment that could affect investor confidence.
- Market Momentum Analysis: With a Benzinga Edge score of 19.82 indicating weak momentum, BioNTech's stock is underperforming the broader market, although the strategic pivot may present future growth opportunities, current market sentiment remains negative.
See More
